EMA 9/21 crossover, 4h, 95% of equity (vol-targeting study: baseline) · ADAUSDT 4h: +1,520.72%

EMA 9/21 crossover, 4h, 95% of equity (vol-targeting study: baseline) · ADAUSDT 4h: +1,520.72% — Janorium backtest